NCT01652079: A trial that was reported late by Massachusetts General Hospital
This trial has reported, although it was 1354 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT01652079 |
|---|---|
| Title | A Phase II, 2-stage Trial of CRLX101 in Combination With Bevacizumab in Recurrent Platinum-Resistant Ovarian, Tubal and Peritoneal Cancer |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | April 30, 2012 |
| Completion date | March 31, 2018 |
| Required reporting date | March 31, 2019, midnight |
| Actual reporting date | Dec. 14, 2022 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | 1354 |